Navigation Links
CRG buys Genomatix' Next Generation Sequencing analysis solution
Date:3/4/2009

The Centre for Genomic Regulation (CRG) in Barcelona, Spain purchased the Genomatix Genome Analyzer (GGA), as announced today by Genomatix Software GmbH.

GGA comprises purpose built high performance hardware and terabytes of proprietary databases and software providing a complete solution for the analysis of Next Generation Sequencing (NGS) data after mapping to the genome.

"In regards to the machine, I love it! And I have advertised it to many colleagues," says Dr. Ramin Shiekhattar, Group Leader within the Gene Regulation Programme.

"We are pursuing research in two major areas. The first is the molecular mechanism of cancer. We are working to address the mechanism by which tumor suppressors such as BRCA1 and BRCA2 exerted their biological effects. Our second avenue of research entails the delineation of the mechanisms by which the genome is silenced through chromatin modification and small regulatory RNA. The laboratory's goal is to understand the epigenetic regulation of gene expression in mammalian development and genetic disease"

Klaus May, Chief Business Officer at Genomatix says:" I am extremely excited that one of our installations of the GGA went to the CRG in Barcelona. This is a very impressive institution with outstanding scientists and cutting edge equipment at a wonderful location. Our GGA definitely fits into that environment and will contribute substantially to the analysis of data produced by their sequencers. "

The Genomatix Genome Analyzer (GGA) delivers all downstream tools and databases for deep biological analysis of mapped data coming from next generation sequencers. It allows for easy integration and visualization within the terabytes of background annotation of the most complete mammalian genome annotation: ElDorado. GGA delivers annotation of genomic coordinates from GMS or any other mapping procedure, clustering and peak finding, analysis for phylogenetic conservation, large scale correlation analysis with any annotated genomic elements, meta-analysis of data correlation between different experiments, pathway mining for groups of identified genes, transcription factor binding site (TFBS) analysis (identification, over-representation, binding partner analysis, framework identification, phylogenetic conservation, regulatory SNP effects) and much more.


'/>"/>

Contact: Klaus May
may@genomatix.de
49-895-997-660
Genomatix Software GmbH
Source:Eurekalert

Related biology news :

1. Boehringer Ingelheim uses Genomatix Next Generation Sequencing data analysis systems
2. Genomatix joins Illumina-Connect program
3. Pfizer inks global license to Genomatix Software and databases
4. NIA uses Genomatix in stem cell research, suggests novel transcription factors for stemness
5. Energy drinks: The coffee of a new generation?
6. New generation of orthopedic, dental and cardiovascular prostheses
7. Next generation microscopy: No stain, big gain
8. e-Smart Technologies to Introduce Next Generation I AM Smart Card Technology at Cartes 2008 in Paris
9. Gene therapy restores vision to mice with retinal degeneration
10. Cholesterol-lowering drugs and the effect on muscle repair and regeneration
11. Generation innovation: Young UC San Diego bioengineer to use NIH grant to fuel tissue engineering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... , March 22, 2017  Ascendis Pharma A/S ... innovative TransCon technology to address significant unmet medical ... for the full year ended December 31, 2016. ... for our company as we broadened our pipeline ... integrated rare disease company with an initial focus ...
(Date:3/22/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... ), a clinical-stage pharmaceutical company focused on the ... that Dr. Miriam Kidron , Oramed,s Chief ... Insulin for Diabetes Treatment: Bypassing the Roadblock," at ... Therapeutics (OPT) Boston Conference in Cambridge, Massachusetts ...
(Date:3/22/2017)... 22, 2017 MarketNewsUpdates.com News Commentary  ... The traditional ... being pressured as of late due to the rise of ... has a dramatic impact on patient,s quality of life as ... for identifying new forms of opioid formulations that prevent abuse. ...
(Date:3/22/2017)... 2017   VWR (NASDAQ: VWR), ... and service solutions to laboratory and production ... EPL Archives, Inc., an international biorepository services ... regulated product research, development and commercialization lifecycle ... ancillary services. EPL Archives is widely recognized ...
Breaking Biology Technology: